Clinical Trial Update: BI 655066 (Risankizumab) Proof of Concept Dose Finding Study in Ankylosing Spondylitis (AS) [Phase 2]

View source ↗

Summary

Phase 2 dose-finding study of risankizumab (BI 655066) in ankylosing spondylitis completed with results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ankylosing Spondylitis

Drugs mentioned

• Risankizumab (risankizumab)

Snippet

Sponsor: AbbVie | Conditions: Ankylosing Spondylitis (AS) | Phase 2 | Status: COMPLETED | Results posted: 2019-05-31